Medulloblastoma in childhood: new biological advances (Q37010548)

17 August 2017

1 reference

title

Medulloblastoma in childhood: new biological advances (English)

1 reference

17 August 2017

0 references

John R Crawford

1

1 reference

PubMed ID

18031705

17 August 2017

Tobey J MacDonald

series ordinal

2

1 reference

PubMed ID

18031705

17 August 2017

Roger J Packer

series ordinal

3

1 reference

17 August 2017

1 December 2007

1 reference

17 August 2017

1 reference

17 August 2017

6

1 reference

17 August 2017

12

1 reference

17 August 2017

1073-1085

1 reference

Current treatment of medulloblastoma: recent advances and future challenges

17 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970289-2

7 January 2021

The molecular basis of Turcot's syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970289-2

7 January 2021

Medulloblastoma and other primary malignant neuroectodermal tumors of the CNS. The effect of patients' age and extent of disease on prognosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970289-2

7 January 2021

The value of myelography in the management of childhood medulloblastoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970289-2

7 January 2021

Is there a correlation between duration of presenting symptoms and stage of medulloblastoma at the time of diagnosis?

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970289-2

7 January 2021

Duration of symptoms prior to diagnosis is related inversely to presenting disease stage in children with medulloblastoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970289-2

7 January 2021

Paediatric medulloblastoma: atypical CT features at presentation in the SIOP II trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970289-2

7 January 2021

Uncommon presentation of medulloblastoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970289-2

7 January 2021

MRI of medulloblastoma in adults.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970289-2

7 January 2021

MRI features of primary, secondary and metastatic medulloblastoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970289-2

7 January 2021

Magnetic resonance spectroscopy suggests key differences in the metastatic behaviour of medulloblastoma

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970289-2

7 January 2021

Taurine detection by proton magnetic resonance spectroscopy in medulloblastoma: contribution to noninvasive differential diagnosis with cerebellar astrocytoma

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970289-2

7 January 2021

[18F]fluorodeoxyglucose-positron emission tomography in patients with medulloblastoma

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970289-2

7 January 2021

Incorporating functional MR imaging into diffusion tensor tractography in the preoperative assessment of the corticospinal tract in patients with brain tumors.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970289-2

7 January 2021

Diffusion tensor imaging of white matter after cranial radiation in children for medulloblastoma: correlation with IQ.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970289-2

7 January 2021

Diffusion tensor magnetic resonance imaging finding of discrepant fractional anisotropy between the frontal and parietal lobes after whole-brain irradiation in childhood medulloblastoma survivors: reflection of regional white matter radiosensitivity

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970289-2

7 January 2021

Differentiation in the medulloblastoma. A histological and immunohistochemical study.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970289-2

7 January 2021

Mitotic percentage index: a new prognostic factor for childhood medulloblastoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970289-2

7 January 2021

"Desmoplastic" versus "classic" medulloblastoma: comparison of DNA content, histopathology and differentiation.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970289-2

7 January 2021

"Large cell/anaplastic" medulloblastomas: a Pediatric Oncology Group Study.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970289-2

7 January 2021

Comparison of lumbar and shunt cerebrospinal fluid specimens for cytologic detection of leptomeningeal disease in pediatric patients with brain tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970289-2

7 January 2021

Medulloblastoma: present concepts of stratification into risk groups

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970289-2

7 January 2021

Immunohistochemical markers for prognosis of average-risk pediatric medulloblastomas. The effect of apoptotic index, TrkC, and c-myc expression.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970289-2

7 January 2021

Medulloblastoma: histopathologic and molecular markers of anaplasia and biologic behavior.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970289-2

7 January 2021

A clinicobiological model predicting survival in medulloblastoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970289-2

7 January 2021

Histopathological prognostic factors in medulloblastoma: high expression of survivin is related to unfavourable outcome.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970289-2

7 January 2021

Prognostic relevance of clinical and biological risk factors in childhood medulloblastoma: results of patients treated in the prospective multicenter trial HIT'91.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970289-2

7 January 2021

Metastasis stage, adjuvant treatment, and residual tumor are prognostic factors for medulloblastoma in children: conclusions from the Children's Cancer Group 921 randomized phase III study.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970289-2

7 January 2021

Treatment of medulloblastoma with postoperative chemotherapy alone: an SFOP prospective trial in young children.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970289-2

7 January 2021

Correlation of neurosurgical subspecialization with outcomes in children with malignant brain tumors.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970289-2

7 January 2021

Cerebellar medulloblastoma: treatment by irradiation of the whole central nervous system.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970289-2

7 January 2021

Treatment of children with medulloblastomas with reduced-dose craniospinal radiation therapy and adjuvant chemotherapy: A Children's Cancer Group Study.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970289-2

7 January 2021

Standard-risk medulloblastoma treated by adjuvant chemotherapy followed by reduced-dose craniospinal radiation therapy: a French Society of Pediatric Oncology Study.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970289-2

7 January 2021

Results of a prospective randomized trial comparing standard dose neuraxis irradiation (3,600 cGy/20) with reduced neuraxis irradiation (2,340 cGy/13) in patients with low-stage medulloblastoma. A Combined Children's Cancer Group-Pediatric Oncology

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970289-2

7 January 2021

Low-stage medulloblastoma: final analysis of trial comparing standard-dose with reduced-dose neuraxis irradiation.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970289-2

7 January 2021

Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicentre trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970289-2

7 January 2021

Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970289-2

7 January 2021

Treatment of high risk medulloblastomas in children above the age of 3 years: a SFOP study.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970289-2

7 January 2021

Updated results of a pilot study of low dose craniospinal irradiation plus chemotherapy for children under five with cerebellar primitive neuroectodermal tumors (medulloblastoma).

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970289-2

7 January 2021

A pilot study of preirradiation chemotherapy and 1800 cGy craniospinal irradiation in young children with medulloblastoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970289-2

7 January 2021

Patterns of failure using a conformal radiation therapy tumor bed boost for medulloblastoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970289-2

7 January 2021

Conformal radiotherapy, reduced boost volume, hyperfractionated radiotherapy, and online quality control in standard-risk medulloblastoma without chemotherapy: results of the French M-SFOP 98 protocol.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970289-2

7 January 2021

Hyperfractionated craniospinal radiation therapy for primitive neuroectodermal tumors: results of a Phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970289-2

7 January 2021

New technologies in radiation therapy for pediatric brain tumors: the rationale for proton radiation therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970289-2

7 January 2021

Current therapy for medulloblastoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970289-2

7 January 2021

Outcome for patients with metastatic (M2-3) medulloblastoma treated with SIOP/UKCCSG PNET-3 chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970289-2

7 January 2021

High-dose chemotherapy with autologous stem cell rescue for children with high risk and recurrent medulloblastoma and supratentorial primitive neuroectodermal tumors.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970289-2

7 January 2021

Results of a randomized study of preradiation chemotherapy versus radiotherapy alone for nonmetastatic medulloblastoma: The International Society of Paediatric Oncology/United Kingdom Children's Cancer Study Group PNET-3 Study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970289-2

7 January 2021

Prospective randomised trial of chemotherapy given before radiotherapy in childhood medulloblastoma. International Society of Paediatric Oncology (SIOP) and the (German) Society of Paediatric Oncology (GPO): SIOP II.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970289-2

7 January 2021

Postoperative neoadjuvant chemotherapy before radiotherapy as compared to immediate radiotherapy followed by maintenance chemotherapy in the treatment of medulloblastoma in childhood: results of the German prospective randomized trial HIT '91.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970289-2

7 January 2021

Impact of targeting deviations on outcome in medulloblastoma: study of the French Society of Pediatric Oncology (SFOP).

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970289-2

7 January 2021

Feasibility of four consecutive high-dose chemotherapy cycles with stem-cell rescue for patients with newly diagnosed medulloblastoma or supratentorial primitive neuroectodermal tumor after craniospinal radiotherapy: results of a collaborative study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970289-2

7 January 2021

Treatment of early childhood medulloblastoma by postoperative chemotherapy alone

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970289-2

7 January 2021

Intrathecal methotrexate affects cognitive function in children with medulloblastoma

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970289-2

7 January 2021

Feasibility and response to induction chemotherapy intensified with high-dose methotrexate for young children with newly diagnosed high-risk disseminated medulloblastoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970289-2

7 January 2021

Intellectual and functional outcome of children 3 years old or younger who have CNS malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970289-2

7 January 2021

A feasibility trial of antiangiogenic (metronomic) chemotherapy in pediatric patients with recurrent or progressive cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970289-2

7 January 2021

Safety and pharmacokinetics of temozolomide using a dose-escalation, metronomic schedule in recurrent paediatric brain tumours

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970289-2

7 January 2021

Understanding the cognitive impact on children who are treated for medulloblastoma

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970289-2

7 January 2021

Long-term neurologic and neurosensory sequelae in adult survivors of a childhood brain tumor: childhood cancer survivor study.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970289-2

7 January 2021

Late-occurring stroke among long-term survivors of childhood leukemia and brain tumors: a report from the Childhood Cancer Survivor Study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970289-2

7 January 2021

'Complicated migraine-like episodes' in children following cranial irradiation and chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970289-2

7 January 2021

Endocrine and cardiovascular late effects among adult survivors of childhood brain tumors: Childhood Cancer Survivor Study.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970289-2

7 January 2021

Final height and body mass index among adult survivors of childhood brain cancer: childhood cancer survivor study.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970289-2

7 January 2021

In search of the medulloblast: neural stem cells and embryonal brain tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970289-2

7 January 2021

The cellular and molecular biology of medulloblastoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970289-2

7 January 2021

What's new in neuro-oncology? Recent advances in medulloblastoma

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970289-2

7 January 2021

Molecular biology of medulloblastoma therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970289-2

7 January 2021

Pathogenesis of medulloblastoma and current treatment outlook.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970289-2

7 January 2021

Molecular genetics of pediatric central nervous system tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970289-2

7 January 2021

The neurobiology of neurooncology.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970289-2

7 January 2021

Medulloblastoma: therapy and biologic considerations.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970289-2

7 January 2021

Molecular biology of medulloblastoma: will it ever make a difference to clinical management?

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970289-2

7 January 2021

Mutations in SUFU predispose to medulloblastoma

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970289-2

7 January 2021

Prediction of central nervous system embryonal tumour outcome based on gene expression

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970289-2

7 January 2021

Isochromosome 17q is a negative prognostic factor in poor-risk childhood medulloblastoma patients

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970289-2

7 January 2021

REN(KCTD11) is a suppressor of Hedgehog signaling and is deleted in human medulloblastoma

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970289-2

7 January 2021

Chromosome 17p deletion in human medulloblastoma: a missing checkpoint in the Hedgehog pathway

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970289-2

7 January 2021

Small molecule modulation of Smoothened activity

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970289-2

7 January 2021

Suppression of the Shh pathway using a small molecule inhibitor eliminates medulloblastoma in Ptc1(+/-)p53(-/-) mice.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970289-2

7 January 2021

Wnt proteins are lipid-modified and can act as stem cell growth factors

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970289-2

7 January 2021

Histopathological and molecular prognostic markers in medulloblastoma: c-myc, N-myc, TrkC, and anaplasia.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970289-2

7 January 2021

c-myc overexpression causes anaplasia in medulloblastoma

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970289-2

7 January 2021

beta-Catenin status predicts a favorable outcome in childhood medulloblastoma: the United Kingdom Children's Cancer Study Group Brain Tumour Committee

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970289-2

7 January 2021

Prognostic significance of the c-erbB-2 oncogene product in childhood medulloblastoma

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970289-2

7 January 2021

Expression profiling of medulloblastoma: PDGFRA and the RAS/MAPK pathway as therapeutic targets for metastatic disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970289-2

7 January 2021

Neurotrophin receptor TrkC predicts good clinical outcome in medulloblastoma and other primitive neuroectodermal brain tumors.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970289-2

7 January 2021

All-trans-retinoic acid induces cell growth arrest in a human medulloblastoma cell line

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970289-2

7 January 2021

BMP-2 mediates retinoid-induced apoptosis in medulloblastoma cells through a paracrine effect.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970289-2

7 January 2021

Notch signalling: a simple pathway becomes complex

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970289-2

7 January 2021

Notch1 and notch2 have opposite effects on embryonal brain tumor growth

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970289-2

7 January 2021

Blocking CXCR4-mediated cyclic AMP suppression inhibits brain tumor growth in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970289-2

7 January 2021

10.1016/S1474-4422(07)70289-2

Identifiers

DOI

1 reference

17 August 2017

1 reference

PubMed ID

18031705